Niagen Bioscience (NAGE) Free Cash Flow (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Free Cash Flow of -$1.2 million for Q1 2026, down 115.15% year-over-year from $7.9 million in Q1 2025, and down 269.6% quarter-over-quarter from $704000.0 in Q4 2025.
Niagen Bioscience (NAGE) Free Cash Flow (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Free Cash Flow for 14 consecutive years, with -$1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 115.15% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at $4.4 million (down 77.52% YoY), while the FY2025 annual figure was $13.5 million, up 11.52% from the prior year.
- Free Cash Flow fell to -$1.2 million in Q1 2026 per NAGE's latest filing, from $704000.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $8.6 million in Q4 2024 and bottomed at -$7.2 million in Q1 2022.
- Historically, Free Cash Flow has averaged $966941.2 across 5 years, with a median of $649000.0 in 2023.
- Annual changes were most pronounced in 2025 — Free Cash Flow surged 2572.2% — and 2026, when it slumped 115.15%.
- Niagen Bioscience's Free Cash Flow stood at -$328000.0 in 2022, then jumped by 297.87% to $649000.0 in 2023, then jumped by 1222.5% to $8.6 million in 2024, then sank by 91.8% to $704000.0 in 2025, then sank by 269.6% to -$1.2 million in 2026.
- Business Quant data shows NAGE's Free Cash Flow at -$1.2 million in Q1 2026, $704000.0 in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn | 2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.77 Mn |
| Jun 30, 2026 | 2.77 Mn |
| Mar 31, 2026 | -1.19 Mn |
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | 704,000.00 |
| Dec 31, 2025 | 704,000.00 |
| Sep 30, 2025 | 3.70 Mn |
| Sep 30, 2025 | 3.70 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 7.88 Mn |
| Mar 31, 2025 | 7.88 Mn |
| Dec 31, 2024 | 8.58 Mn |
| Dec 31, 2024 | 8.58 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | -264,000.00 |
| Jun 30, 2024 | -264,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Mar 31, 2024 | 295,000.00 |